Physician profile
Joseph Richichi
NPI 1760553770
$540.46
in general payments reported to CMS, 2019-2025
14 companies · $20.04 in 2025
The $20.04 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.03 · 2020: $279 · 2021: $175 · 2025: $20.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $81.84 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $78.31 | 2020-2021 | |
| Novo Nordisk INC | $56.60 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.95 | 2020-2021 | |
| Pfizer INC. | $52.41 | 2019-2021 | |
| Amarin Pharma, INC. | $41.61 | 2020-2021 | |
| Allergan, INC. | $34.69 | 2020 | |
| Glaxosmithkline, LLC. | $30.42 | 2019-2021 | |
| Abbvie INC. | $21.29 | 2021 | |
| Antares Pharma, INC. | $20.10 | 2020 | |
| Medtronic, INC. | $20.04 | 2025 | Inceptiv |
| Biohaven Pharmaceuticals, INC. | $18.77 | 2020 | |
| Lilly USA, LLC | $14.77 | 2021 | |
| Kvk-Tech, INC. | $14.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Richichi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.